Techno Drugs (DHA:TECHNODRUG) PE Ratio: 30.92 (As of Jul. 24, 2026) — 56% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:TECHNODRUG Techno Drugs Ltd DHA:TECHNODRUG
37 GF Score
Price BDT47.30
! 10 Warning Signs
View Full Analysis

What is Techno Drugs PE Ratio?

Techno Drugs DHA:TECHNODRUG -2.27% 37 PE Ratio is 30.92 as of Jul. 24, 2026, which is 56% above its 10-year median of 19.81. GuruFocus rates DHA:TECHNODRUG with a GF Score™ of 37/100. The stock has 10 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-24), Techno Drugs's share price is BDT47.30. Techno Drugs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was BDT1.53. Therefore, Techno Drugs's PE Ratio for today is 30.92.

Warning Sign:

Techno Drugs Ltd stock PE Ratio (=30.65) is close to 3-year high of 30.65.

During the past 2 years, Techno Drugs's highest PE Ratio was 32.68. The lowest was 14.61. And the median was 19.81.

Techno Drugs's EPS (Diluted) for the three months ended in Mar. 2026 was BDT0.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was BDT1.53.

As of today (2026-07-24), Techno Drugs's share price is BDT47.30. Techno Drugs's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was BDT1.53. Therefore, Techno Drugs's PE Ratio without NRI ratio for today is 30.92.

During the past 2 years, Techno Drugs's highest PE Ratio without NRI was 32.68. The lowest was 14.61. And the median was 19.81.

Techno Drugs's EPS without NRI for the three months ended in Mar. 2026 was BDT0.31. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was BDT1.53.

During the past 12 months, Techno Drugs's average EPS without NRI Growth Rate was -11.30% per year.

Techno Drugs's EPS (Basic) for the three months ended in Mar. 2026 was BDT0.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was BDT1.53.

Back to Basics: PE Ratio


Techno Drugs  (DHA:TECHNODRUG) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Techno Drugs PE Ratio Related Terms


Techno Drugs PE Ratio Historical Data

* Premium members only.

The historical data trend for Techno Drugs's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Techno Drugs PE Ratio Chart

Techno Drugs Annual Data
Trend Jun24 Jun25
PE Ratio
N/A 15.97

Techno Drugs Quarterly Data
Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 18.43 15.97 22.82 18.77 23.07

DHA:TECHNODRUG vs ZTS, UTHR, VTRS: PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Techno Drugs's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Techno Drugs PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Techno Drugs's PE Ratio distribution charts can be found below:

* The bar in red indicates where Techno Drugs's PE Ratio falls into.


DHA:TECHNODRUG
37GF Score
Techno Drugs Ltd DHA:TECHNODRUG
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Techno Drugs PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Techno Drugs's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=47.30/1.530
=30.92

Techno Drugs's Share Price of today is BDT47.30.
Techno Drugs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT1.53.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 30.92 mean?
Techno Drugs (DHA:TECHNODRUG) has a PE Ratio of 30.92 as of Jul. 24, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Techno Drugs and its competitors. This is 56% above median its historical median of 19.81. Over the past decade, Techno Drugs' PE Ratio has ranged from 14.61 to 32.68.
Is Techno Drugs' PE Ratio too high?
Techno Drugs' current PE Ratio of 30.92 is 56% above median its 10-year median of 19.81. Over the past 10 years, this metric has ranged from a low of 14.61 to a high of 32.68. Overall, Techno Drugs has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Techno Drugs' PE Ratio compare to ZTS and UTHR?
Techno Drugs' PE Ratio of 30.92 can be compared against companies in the Drug Manufacturers industry. Historically, Techno Drugs' own PE Ratio has ranged from 14.61 to 32.68 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Drug Manufacturers company?
A good PE Ratio depends on the Drug Manufacturers industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Techno Drugs and its competitors. Techno Drugs's current PE Ratio is 30.92, which is 56% above median its own 10-year median of 19.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Techno Drugs stock overvalued right now?
Techno Drugs (DHA:TECHNODRUG) has a current PE Ratio of 30.92. The current PE Ratio is 30.92, which is 56% above median its 10-year median of 19.81. Techno Drugs' overall GF Score™ is 37/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Techno Drugs (DHA:TECHNODRUG), the current PE Ratio is 30.92 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Techno Drugs Business Description

Address 31 Segun Bagicha, J K Tower, Dhaka, BGD, 1000
Techno Drugs Ltd is a pharmaceutical company. The company manufactures medicines for the healthcare market with quality products, a distribution channel, and doctor-patient acceptance. The company is also engaged in production of Anti-Cancer medicines and medicines for therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, life-saving antibiotics & contrast media in Bangladesh. The product portfolio of the company include Algicar Plus, Amoclav Forte, Adesol Oral Solution, Aminovet Injection, Apegestrol Tab, Docetex 20 Inj, and others.
37GF Score

Get the complete analysis for DHA:TECHNODRUG

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT47.30
Price